FDA Policy Change Would Make It Easier To Start Pivotal Trials
This article was originally published in The Gray Sheet
Executive Summary
FDA is changing the way it vets clinical trial plans to allow firms to start pivotal trials earlier while still ensuring that the study data ultimately supports a pre-market application.